SEC For	m 4 FORM	4	UNITED	) STA	TES	s se	ECUR	ITIE		Ε	ХСНА	NGE		ommi	SSION					
							V	Vashin	(	OMB APPROVAL										
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP												OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
or Section 30(h) of the Investment Company Act of 1940																				
1. Name and Address of Reporting Person <sup>*</sup> LEE KENNETH B JR					<u>B</u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC									elationship o eck all applio X Directo	able)	10% Owner			
(Last) (First) (Middle) 4505 EMPEROR BLVD., SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 06/07/2022									(give title		Other (s below)	pecify		
(Street) DURHAM NC 27703				4.1	Line) X Form fi									oint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting			1			
(City)	(S	tate)	(Zip)		Person															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date				2. Trans Date (Month/I		ar) i	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction I Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)		(A) or 3, 4 and		s ally ollowing	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		A) or D)	Price	Reported Transact (Instr. 3 a	ion(s)				
Common Stock 0				06/07	7/202	/2022			Α		12,866	(1)	Α	\$ <mark>0</mark>		37,118		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, 1	i. ransaction Code (Instr. i)				6. Date Exercisable Expiration Date (Month/Day/Year)		•	nd 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	0 N 0	lumber						
Automatic Stock Option Grant <sup>(2)</sup>	\$10.79	06/07/2022			А		30,022		06/07/2023	3 0	06/07/2032	Comn Stoc		30,022	\$0	30,022	2	D		

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

/s/ Alane P. Barnes, by power	0.000
of attorney	<u>06/09/2022</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.